bioRxivBioinformaticsPreprint
From Transcriptomic Signatures to Active-Site Docking and ADMET Properties Prediction: Bioinformatics-Guided Exploration of Binding Mechanisms of Cardioprotective Phytoconstituents Against Dysregulated Targets in Hypertrophic Cardiomyopathy
Basavaraj Mallikarjunayya VastradiD, Shivaling PattanashettiiD, Chanabasayya Mallikarjunayya VastradiD
Abstract
Hypertrophic cardiomyopathy (HCM) is a global health problem characterized by left ventricle become thick and stiff with effect of indication including chest pain, fluttering, fainting and shortness of breath. In this investigation, we aimed to identify diagnostic markers and analyzed the therapeutic potential of essential genes. Next generation sequencing (NGS) dataset GSE180313 was obtained from the Gene Expression Omnibus (GEO) database and used to identify differentially expressed genes (DEGs) in HCM. DEGs were screened using the DESeq2 Rbioconductor tool. Then, Gene Ontology (GO) and REACTOME pathway enrichment analyses were performed. Moreover, a protein-protein interaction (PPI) network of the DEGs was constructed, and module analysis was performed. Next, miRNA-hub gene regulatory network, TF-hub gene regulatory network and drug-hub gene interaction network were constructed and analyzed. Next, diagnostic values of hub genes were assessed by receiver operating characteristic (ROC) curve analysis. Finely, molecular docking and ADMET studies were performed. By performing DEGs analysis, total 958 DEGs ( 479 up regulated genes and 479 down regulated genes) were successfully identified from GSE180313, respectively. GO and REACTOME pathway enrichment analyses revealed that GO functions and signaling pathways were significantly enriched including response to stimulus, multicellular organismal process, metabolism and extracellular matrix organization. The hub genes of FN1, SOX2, TUBA4A, RPS2, TUBA1C, ESR1, SNCA, LCK, PAK1 and APLNR might be associated with HCM. The hub gens of FN1 and TPM3, together with corresponding predicted miRNAs (e.g., hsa-mir-374a-5p and hsa-miR-8052), SH3KBP1 and ESR1 together with corresponding predicted TFs (e.g PRRX2 and STAT3) and CHRNA4 and CHRM3 together with corresponding predicted drug molecules (e.g. Succinylcholine and Umeclidinium) were found to be significantly correlated with HCM. Molecular Docking study revealed that all tested phytoconstituents effectively occupied LGALS3 and ESR1. ADMET analysis found that all screened compounds have adequate solubility and high projected intestine absorption, indicating their appropriateness for oral administration, This investigation could serve as a basis for further understanding the molecular pathogenesis and potential therapeutic targets of HCM.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: statistical model
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Lineage-specific regulatory changes in the pathological cardiac remodeling of hypertrophy cardiomyopathy unraveled by single-nucleus RNA-seq and spatial transcriptomics
- Identification of candidate biomarkers and therapeutic agents for heart failure by bioinformatics analysis
Vijayakrishna Kolur, Basavaraj Mallikarjunayya Vastrad, … Anandkumar Tengli·BMC Cardiovascular DisordersPeer-reviewed·Jul 4, 2021
- Transcriptomic signature of Human Cardiac Fibroblast in Hypertrophic Obstructive Cardiomyopathy
Ayman Maher Ibrahim, Sarah Halawa, … Magdi Habib Yacoub·bioRxiv·Jul 17, 2026
- Identification of biomarkers, pathways and potential therapeutic targets for heart failure using bioinformatics analysis
Basavaraj Mallikarjunayya Vastrad, Chanabasayya Mallikarjunayya Vastrad·bioRxiv·Aug 5, 2021
- Histone Modifications and miRNA Perturbations Contribute to Transcriptional Dysregulation of Hypertrophy in Obstructive Hypertrophic Cardiomyopathy
Ramin Garmany, Surendra Dasari, … Michael John Ackerman·bioRxiv·May 9, 2024
- Metabolic and Proteomic Defects in Human Hypertrophic Cardiomyopathy
M. Previs, T. O'Leary, … S. Day·bioRxiv·Aug 18, 2021